Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

Integrins αvβ3 and αvβ5 regulate angiogenesis and invasiveness in cancer, potentially by modulating activation of the transforming growth factor (TGF)-β pathway. The randomized phase III CENTRIC and phase II CORE trials explored the integrin inhibitor cilengitide in patients with newly diagnosed gli...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Weller, Michael, Nabors, Louis Burt, Gorlia, Thierry, Leske, Henning, Rushing, Elisabeth, Bady, Pierre, Hicking, Christine, Perry, James, Hong, Yong-Kil, Roth, Patrick, Wick, Wolfgang, Goodman, Simon L., Hegi, Monika E., Picard, Martin, Moch, Holger, Straub, Josef, Stupp, Roger
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924768/
https://ncbi.nlm.nih.gov/pubmed/26918452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7588
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia